Dana Dolce
Adult Health · Stanford, CANPI 1548329865
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 217 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,863, more than ten times the $137 reported in 2021. Among adult health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Medtronic$978
- UCB, Inc.$488
- Boston Scientific$448
- Insightec,inc$366
- Teva Pharmaceuticals USA, Inc.$262
- plus $1K from 24 others
What the payments were for
- Food & beverage$5,15999%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 29 | $1,227 |
| Medtronic | 34 | $978 |
| UCB, Inc. | 32 | $488 |
| Boston Scientific | 12 | $448 |
| Insightec,inc | 10 | $366 |
| Teva Pharmaceuticals USA, Inc. | 17 | $262 |
| Lundbeck LLC | 8 | $139 |
| Neurelis, Inc. | 8 | $127 |
| Servier Pharmaceuticals LLC | 7 | $120 |
| Amneal Pharmaceuticals LLC | 7 | $119 |
| Neurocrine Biosciences, Inc. | 6 | $106 |
| Argenx US, Inc. | 6 | $102 |
| SK Life Science, Inc. | 6 | $94 |
| Tanabe Pharma America, Inc. | 5 | $80 |
| Integra Lifesciences Corporation | 2 | $76 |
| Tonix Medicines, Inc. | 5 | $76 |
| Corcept Therapeutics | 3 | $60 |
| Merz Pharmaceuticals, LLC | 3 | $50 |
| Jazz Pharmaceuticals Inc. | 3 | $49 |
| Biogen | 2 | $37 |
| Springworks Therapeutics, Inc. | 2 | $33 |
| AstraZeneca(2 entities) | 2 | $30 |
| Livanova USA, Inc. | 1 | $21 |
| Novocure Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Electromed, Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Aucta Pharmaceuticals, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $14 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$780
- GENERAL DBS$227
- SenSight$130
- Exablate$118
- PERCEPT PC BRAINSENSE$108
How this compares
$5,204 in reported general payments places this provider in the 90th percentile of 785 adult health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 19 | $188,180 |
| NuplazidPimavanserin Tartrate | 14 | $66,920 |
| RytaryCarbidopa/Levodopa | 64 | $56,927 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 256 | $13,773 |
| Entacapone | 27 | $8,515 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 28 | $2,810 |
| Primidone | 71 | $2,777 |
| Quetiapine Fumarate | 28 | $1,715 |
| AmantadineAmantadine Hcl | 19 | $1,329 |
| Mirtazapine | 51 | $1,296 |
| Rasagiline Mesylate | 12 | $1,179 |
| Donepezil Hcl | 21 | $1,069 |
| RivastigmineRivastigmine Tartrate | 11 | $935 |
| Clonazepam | 86 | $759 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 31 | $743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $262 | $188,18019 claims |
| Amneal Pharmaceuticals LLCRytary | $119 | $56,92764 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 785 adult health providers in California.
Other adult health in Stanford
- Karolina FaysmanLos Angeles$1.1M
- Linda BuckLos Angeles$170K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
- Brittany PolizziEncinitas$35K
- Nancy NicolosiLaguna Woods$31K
- Michele WestendorfNewport Beach$30K
- Lisa HinemanLos Angeles$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.